Tus kws kho mob
P77-17 Medicare Advantage Process for NOMNC Letter
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 12, 2017
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 3201 - 3210 ntawm 3669
Tus kws kho mob
P3-18 New Drug-Related PA Criteria: Inhaled Antibiotics Duplicate Therapy
Hnub Tim pib siv tau lub khoos kas: Lub Ib Hlis Ntuj 24, 2018
Tus kws kho mob
Medical Management Referral Form
Tus kws kho mob
P43-17 New Drug-Related Prior Authorization Criteria for Symbicort
Hnub Tim pib siv tau lub khoos kas: Lub Yim Hlis Ntuj Tim 07, 2017
Tus kws kho mob
P23-18 Clinical Reviews for Court-Ordered Substance Use Disorder Treatment
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P2R1-18 Updated: New Medical Drug Prior Authorization Requirements for Voretigene Neparvovec (Luxturna)
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 02, 2018
Tus kws kho mob
P76-17 Centurion moving to Blue Cross for Claims Administration Services
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 07, 2017
Tus kws kho mob
P1-18 New Drugs, Aimovig (erenumab), Fremanezumab and Galcanezumab Will Require PA
Hnub Tim pib siv tau lub khoos kas: Lub Ib Hlis Ntuj 09, 2018
Tus kws kho mob
2018 May Bulletins
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 01, 2018
Tus kws kho mob
P25-17 Addition of New Drugs to the Hepatitis C Second Generation Antivirals Prior Authorization (PA) with Quantity Limit (QL) Program
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 25, 2017